Mission: Raise Awareness of Japanese Medicinal Mushroom Among Cancer, AIDS & Hepatitis Patients
RYE, N.Y., April 13, 2001 — Building upon 14 years of patient success in Japan, the Active Hexose Correlated Compound’s (AHCC®) Research Association has been established to communicate the nutritional supplement’s benefits to U.S. patients. During the next year, the association will undertake an aggressive public education program, reaching out to those with cancer, AIDS, hepatitis and other immune dysfunctions.
Fred Pescatore, M.D., M.P.H., is the medical director for the association and played an integral role in its formation.
“AHCC has been the subject of a great deal of clinical research and our goal is to bring that information to light in the U.S.,” noted Pescatore. “Each year the International AHCC Symposium is held in Sapporo, Japan, in which leading doctors present clinical studies conducted during the previous year. Past topics include cancer tumor reduction, hepatitis B and C treatment, liver injuries, and even post-operative immune support regimen.”
AHCC is derived from a highly specialized manufacturing process developed in the mid-1980s that relies on the hybridization of several species of mushrooms cultivated in Japan.
According to industry analysts in Japan, currently over 700 hospitals and medical clinics recommend AHCC to patients in that country as part of an immune support regimen, creating a $150 million (USD) industry. This has led to 35,000 individuals worldwide using the nutrition supplement monthly.
The AHCC Research Association is undertaking an aggressive public relations program to promote the benefits of AHCC®. For more information, visit www.AHCCresearch.com.
# # #